In a research report issued today, Cantor analyst Daniel Brims reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price target, following …
Cantor’s analyst Daniel Brims weighed in on Celsion Corporation (NASDAQ:CLSN), after the company reported updated results from its retrospective analysis of the Company’s 701-patient HEAT Study of ThermoDox, …
In a research report issued today, Cantor analyst Daniel Brims reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a price target of …
In a research report sent to investors today this morning, Cantor analyst Daniel Brims reiterated a Buy rating on Tetraphase Pharmaceuticals (NASDAQ:TTPH) and raised …
In a research note released today, Cantor Fitzgerald analyst Daniel Brims reaffirmed a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $14 price …
